SCHEMBL2806419

SCHEMBL2806419

O=C(O)CCN(CCC(=O)O)c1ccc(C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GMNN O75496 1/20 0.47
LMNA P02545 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
GABRA1 P14867 1/20 0.47
NFKB1 P19838 1/20 0.47
THPO P40225 1/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
SLCO1B3 Q9NPD5 1/20 0.47
GSK3B P49841 1/20 0.43
SRD5A2 P31213 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665573 0.82 TSHR (0.50) TSHRTP53ALDH1A1SMN1; SMN2SRD5A2
SCHEMBL9103803 0.82 CYP1A1 (0.53) TSHRALDH1A1SMN1; SMN2GMNNLMNA
SCHEMBL2804456 0.81 SMN1; SMN2 (0.47) TSHRTP53ALDH1A1SMN1; SMN2GMNN
SCHEMBL2805280 0.80 KMT2A (0.50) TSHRALDH1A1SMN1; SMN2GMNNLMNA
SCHEMBL472318 0.80 HCAR3 (0.57) TSHRTP53ALDH1A1SMN1; SMN2KMT2A
SCHEMBL20187701 0.80 TSHR (0.48) TSHRTP53ALDH1A1SMN1; SMN2SRD5A2
SCHEMBL766052 0.80 EGFR (0.61) TSHRTP53ALDH1A1SMN1; SMN2GMNN
SCHEMBL7460843 0.80 TSHR (0.48) TSHRTP53ALDH1A1SMN1; SMN2SRD5A2
SCHEMBL342127 0.79 TSHR (0.52) TSHRTP53ALDH1A1SMN1; SMN2SRD5A2
SCHEMBL1230226 0.78 RARB (0.47) TSHRTP53ALDH1A1SMN1; SMN2GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 TSHR 4385/4885TP53 964/4885ALDH1A1 1901/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB TSHR 4263/4885TP53 1857/4885ALDH1A1 4765/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA TSHR 2885/4885TP53 1009/4885ALDH1A1 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.